Results 11 to 20 of about 4,595,974 (209)

DIRECT ORAL ANTICOAGULANTS

Акушерство, гинекология и репродукция, 2016
Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications.
I. Tzoran, B. Brenner
doaj   +1 more source

Gastrointestinal protection options for direct oral anticoagulants in patients with atrial fibrillation

, 2022
Gastrointestinal bleeding (GIB) associated with the use of direct oral anticoagulants or, as they are also called, new oral anticoagulants (NOAC) is a serious medical problem, the relevance of which will only increase taking into account the constant ...
Natalya M. Vorobyeva, Olga N. Tkacheva, Irina P. Malaya, Alexandra M. Lelkova   +3 more
core   +1 more source

Direct oral anticoagulants: first airbag

Медицинский совет, 2019
The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj   +1 more source

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation

Clinical Case Reports, 2022
Venous thromboembolism is often treated with direct oral anticoagulants. In order for direct oral anticoagulants to be effective, patients must adhere to a specific dosing strategy.
Trisha E Jethwa, Kaitlin M Moran, Michael J Maniaci   +2 more
doaj   +1 more source

Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.

PLoS ONE, 2020
BACKGROUND:Warfarin is an anticoagulant medication proven effective in the initial treatment and secondary prevention of venous thromboembolism. Anti-Xa direct oral anticoagulants are alternatives to warfarin; however there is limited data assessing ...
Thomas Hendriks, Scott McGregor, Shilpa Rakesh, Julie Robinson, Kwok M Ho, Ross Baker   +5 more
doaj   +1 more source

Oral anticoagulants: Optimizing venous thromboembolism management

Journal of Applied Hematology, 2019
A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj   +1 more source

Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants

, 2021
Background: Patient's adherence to oral anticoagulant therapy is essential to prevent and treat thrombotic events. Methods: To assess the patients' adherence Morisky Medication Adherence Scale 8-items was used.
Perra F., Marongiu F., Barcellona D., Cornacchini S., Farci N., Diovaldi M., Moledda V., Mameli A., Nicola Farci, Marina Diovaldi, Doris Barcellona, Francesco Marongiu, Antonella Mameli, Valentina Moledda, Flaminia Perra, Simona Cornacchini   +15 more
core   +1 more source

Is it necessary to alter anticoagulation therapy for tooth extraction in patients taking direct oral anticoagulants? [PDF]

, 2017
PubMedID: 29053656Background: The number of patients using direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VKA) is increasing and there is limited data on the safety of tooth extractions in patients taking DOACs.
Tükel H.-C., Caliskan M., Deniz A., Benlidayi M.-E.   +3 more
core   +2 more sources

Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation

Monaldi Archives for Chest Disease, 2020
The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano, Matteo Parollo, Ester Taurino, Elena Venturi, Massimo Santini   +4 more
doaj   +1 more source

Recurrent Left Ventricular Thrombus Formation on Rivaroxaban Therapy in Cardiomyopathy and Liver Cirrhosis

JACC: Case Reports, 2020
Left ventricular (LV) thrombus in patients with reduced LV systolic function carries significant thromboembolic risk. Direct oral anticoagulants are an attractive alternative to warfarin for LV thrombus management.
Usman Ghani, MD, Karlo A. Wiley, BS, Raman Singhal, MD, Cristina Sanina, MD   +3 more
doaj   +1 more source